Prosecution Insights
Last updated: November 04, 2026
Application No. 17/723,553

METHODS FOR DEVELOPING VIRUS PROTEIN-SPECIFIC CAPTURE AGENTS, CAPTURE AGENTS, AND METHODS OF USING THE CAPTURE AGENTS

Non-Final OA §112
Filed
Apr 19, 2022
Priority
May 09, 2019 — continuation of 11/613,746
Examiner
FLINDERS, JEREMY C
Art Unit
1684
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
U.S. Army DEVCOM Army Research Laboratory
OA Round
3 (Non-Final)
63%
Grant Probability
Moderate
3-4
OA Rounds
0m
Est. Remaining
80%
With Interview

Examiner Intelligence

Grants 63% of resolved cases
63%
Career Allowance Rate
390 granted / 615 resolved
+3.4% vs TC avg
Strong +17% interview lift
Without
With
+17.1%
Interview Lift
resolved cases with interview
Typical timeline
3y 9m
Avg Prosecution
47 currently pending
Career history
669
Total Applications
across all art units

Statute-Specific Performance

§101
9.4%
-30.6% vs TC avg
§103
33.6%
-6.4% vs TC avg
§102
25.2%
-14.8% vs TC avg
§112
22.9%
-17.1% vs TC avg
Black line = Tech Center average estimate • Based on career data from 615 resolved cases

Office Action

§112
DETAILED ACTION Status of the Claims Claims 1-23 are currently pending and are the subject of this Office action. The following Office Action is in response to Applicant’s communication dated 02/23/2026. Rejection(s) and/or objection(s) not reiterated from previous office actions are hereby withdrawn. The following rejection(s) and/or objection(s) are either reiterated or newly applied. They constitute the complete set presently being applied to the instant application. A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 02/23/2026 has been entered. The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Claim Interpretation As per MPEP § 2111 and § 2111.01, “[d]uring patent examination, the pending claims must be ‘given their broadest reasonable interpretation consistent with the specification’" and the words of a claim must be given their ‘plain meaning’ unless such meaning is inconsistent with the specification, wherein ‘plain meaning’ of a term means the ordinary and customary meaning given to the term by those of ordinary skill in the art at the relevant time. The ordinary and customary meaning of a term may be evidenced by a variety of sources, including the words of the claims themselves, the specification, drawings, and prior art. Because applicant has the opportunity to amend the claims during prosecution, giving a claim its broadest reasonable interpretation will reduce the possibility that the claim, once issued, will be interpreted more broadly than is justified. In re Yamamoto, 740 F.2d 1569, 1571 (Fed. Cir. 1984) Below are notes made by the examiner regarding claim interpretation of the most recent set of claims. Applicant is respectfully invited to comment on or dispute any of these statements. Claim 1 recites “a construct molecule … comprising: one or more polymer arms having a peptide sequence comprising a five variable amino acid sequence selected from the group consisting of” SEQ ID NOs: 1-4 (emphasis added). As per MPEP § 2111.03, the transitional phrase “comprising” is inclusive or open-ended and does not exclude additional, unrecited elements. Therefore, the composition of the peptides is being interpreted as being open to include additional, unrecited elements, such as other amino acids, thus also encompassing embodiments wherein the sequences of SEQ ID NOs: 1-4 are embedded in a larger polypeptide chain. Claims 2-17 depend from claim 1 and therefore import all the limitations of that claim. Independent claims 18 and 19 (and dependent claim 20 by incorporation) use comparable “comprising” terminology and are therefore similarly interpreted as possibly including additional amino acids in the claimed peptide sequence. In contrast, claim 21 limits the (cyclic) peptide sequence to consist of the five variable amino acid sequence of claim 1. Claims 22 and 23 have claim scopes that are unascertainable (see below). Declaration Under 37 C.F.R. § 1.132 The declaration under 37 CFR 1.132 filed 02/23/206 is insufficient to overcome the rejection of claims 1-23 based upon insufficiency of written description support in the disclosure under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph as set forth in the last Office action. All arguments and issues presented in the declaration, as well as in the 02/23/2026 remarks, are addressed below in the Response to Arguments section. Claim Objections Claim 1 is objected to because of the following informalities: claim 1 recites the term “sequence_selected” in line 4. The use of an underscore is used in amended claims to indicate the addition of text. As per 37 C.F.R. 1.121 (Manner of making amendments in applications), claims that are amended by Applicant are required to be properly marked up (e.g. strikethrough for deletion and underling for insertions) and labeled with the correct status identifier (e.g. original, currently amended, previously presented, withdrawn, canceled, new, or not entered). Appropriate correction is required. See MEPEP 714(II)(C) for further information and guidance. Claim 21 is objected to as being dependent upon a rejected base claim, but would be allowed if rewritten in independent form including all of the limitations of the base claim and any intervening claims. Appropriate correction is required. Claim Rejections - 35 USC § 112(b) -- Indefiniteness The following is a quotation of 35 U.S.C. 112(b): (B) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 22-23 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor, or for pre-AIA the applicant regards as the invention. Claim 22 recites the limitation "the one or more polymer arms" of claim 18. There is insufficient antecedent basis for this limitation in the claim. Accordingly, the metes and bounds of the claim are unascertainable and therefore cannot be examined further. Claim 23 recites the limitation "the one or more polymer arms" of claim 19. There is insufficient antecedent basis for this limitation in the claim. Accordingly, the metes and bounds of the claim are unascertainable and therefore cannot be examined further. As per MPEP 2173: It is of utmost importance that patents issue with definite claims that clearly and precisely inform persons skilled in the art of the boundaries of protected subject matter. Therefore, claims that do not meet this standard must be rejected under 35 U.S.C. 112(b) or pre-AIA 35 U.S.C. 112, second paragraph as indefinite. Further, as per MPEP 2173.02: If the language of the claim is such that a person of ordinary skill in the art could not interpret the metes and bounds of the claim so as to understand how to avoid infringement, a rejection of the claim under 35 U.S.C. 112, second paragraph, would be appropriate. As currently written, the metes and bounds of the rejected claims are unascertainable for the reasons set forth above, thus the above claim(s) and all dependent claims are rejected under 35 USC 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph. Claim Rejection(s) - 35 USC § 112(a) – Written Description The following is a quotation of 35 U.S.C. 112(a): (a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), first paragraph: The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention. Claims 1-20 are rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the written description requirement. The claims contain subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor or a joint inventor, or for pre-AIA the inventor(s), at the time the application was filed, had possession of the claimed invention. To satisfy the written description requirement, a patent specification must describe the claimed invention in sufficient detail that one skilled in the art can reasonably conclude that the inventor had possession of the claimed invention. See, e.g., Moba, B.V. v. Diamond Automation, Inc., 325 F.3d 1306, 1319, 66 USPQ2d 1429, 1438 (Fed. Cir. 2003); Vas-Cath, Inc. v. Mahurkar, 935 F.2d at 1563, 19 USPQ2d at 1116. As per MPEP 2163.02, the courts have described the essential question to be addressed in a description requirement issue in a variety of ways. An objective standard for determining compliance with the written description requirement is, "does the description clearly allow persons of ordinary skill in the art to recognize that he or she invented what is claimed." In re Gosteli, 872 F.2d 1008, 1012, 10 USPQ2d 1614, 1618 (Fed. Cir. 1989). Under Vas-Cath, Inc. v. Mahurkar, 935 F.2d 1555, 1563-64, 19 USPQ2d 1111, 1117 (Fed. Cir. 1991), to satisfy the written description requirement, an applicant must convey with reasonable clarity to those skilled in the art that, as of the filing date sought, he or she was in possession of the invention, and that the invention, in that context, is whatever is now claimed. Possession may be shown in a variety of ways including description of an actual reduction to practice, or by showing that the invention was "ready for patenting" such as by the disclosure of drawings or structural chemical formulas that show that the invention was complete, or by describing distinguishing identifying characteristics sufficient to show that the applicant was in possession of the claimed invention. See, e.g., Pfaff v. Wells Elecs., Inc., 525 U.S. 55, 68, 119 S.Ct. 304, 312, 48 USPQ2d 1641, 1647 (1998); Regents of the Univ. of Cal. v. Eli Lilly, 119 F.3d 1559, 1568, 43 USPQ2d 1398, 1406 (Fed. Cir. 1997); Amgen, Inc. v. Chugai Pharm., 927 F.2d 1200, 1206, 18 USPQ2d 1016, 1021 (Fed. Cir. 1991) (one must define a compound by "whatever characteristics sufficiently distinguish it"). Other ways of establishing possession of a claimed invention may include unique cleavage by particular enzymes, isoelectric points of fragments, detailed restriction enzyme maps, a comparison of enzymatic activities, or antibody cross-reactivity. See Lockwood, 107 F.3d at 1572, 41 USPQ2d at 1966 (Stating that the written description requirement may be satisfied by using "such descriptive means as words, structures, figures, diagrams, formulas, etc., that fully set forth the claimed invention."). Conversely, describing a composition by its function alone typically will not suffice to sufficiently describe the composition. See Eli Lilly, 119 F.3 at 1568, 43 USPQ2d at 1406 (Holding that description of a gene’s function will not enable claims to the gene "because it is only an indication of what the gene does, rather than what it is."); see also Fiers, 984 F.2d at 1169-71, 25 USPQ2d at 1605-06 (discussing Amgen Inc. v. Chugai Pharm. Co., 927 F.2d 1200, 18 USPQ2d 1016 (Fed. Cir. 1991)). An adequate written description of a chemical invention also requires a precise definition, such as by structure, formula, chemical name, or physical properties, and not merely a wish or plan for obtaining the chemical invention claimed. See, e.g., Univ. of Rochester v. G.D. Searle & Co., 358 F.3d 916, 927, 69 USPQ2d 1886, 1894-95 (Fed. Cir. 2004) (The patent at issue claimed a method of selectively inhibiting PGHS-2 activity by administering a non-steroidal compound that selectively inhibits activity of the PGHS-2 gene product, however the patent did not disclose any compounds that can be used in the claimed methods. While there was a description of assays for screening compounds to identify those that inhibit the expression or activity of the PGHS-2 gene product, there was no disclosure of which peptides, polynucleotides, and small organic molecules selectively inhibit PGHS-2. The court held that "[w]ithout such disclosure, the claimed methods cannot be said to have been described."). Finally, MPEP 2163.04 describes the burden on the examiner with regard to the Written Description requirement, stating that in rejecting a claim, the examiner must set forth express findings of fact which support the lack of written description conclusion. These findings should: (A) Identify the claim limitation(s) at issue; and (B) Establish a prima facie case by providing reasons why a person skilled in the art at the time the application was filed would not have recognized that the inventor was in possession of the invention as claimed in view of the disclosure of the application as filed. In the present case, while the disclosure as originally filed has adequate written description support for a small subset of species of construct molecules of the claimed genus, it does not support the full breadth of the claims as currently written. Specifically, the scope of claims 1-20 as currently written reasonably includes the genus of construct molecules with cyclic or non-cyclic (e.g., linear or branched) peptides, as well as peptides with any number of amino acid positions, so long as they include SEQ ID NOs: 1-4 embedded therein (also detailed in the Claim Interpretation section, above). However, the disclosure as originally filed has adequate written description support for a much narrower scope and number of species. Specifically, the specification and drawings detail synthesis, screening, and use only of cyclic peptides consisting of five variable amino acids (e.g., as shown in Fig. 2 and detailed in [0028]), with an actual reduction to practice of construct molecules consisting of SEQ ID NOs: 1-4 and permutations thereof (e.g., as per Fig. 4 and 8-9). Also shown are functioning examples of these constructs in the context of one- and multi-arm constructs (e.g., as per Fig. 3), with various polymers, and configured as capture agents or not (i.e., with or without beads and/or detection labels). Importantly, the disclosure shows measurable affinity of only these constructs for the CHIKV E2 protein, as required by the claims. As per MPEP § 2163, “[t]he written description requirement for a claimed genus may be satisfied through sufficient description of a representative number of species by actual reduction to practice, reduction to drawings, or by disclosure of relevant, identifying characteristics, i.e., structure or other physical and/or chemical properties, by functional characteristics coupled with a known or disclosed correlation between function and structure, or by a combination of such identifying characteristics, sufficient to show the inventor was in possession of the claimed genus” (some citations omitted), wherein a “’representative number of species’ means that the species which are adequately described are representative of the entire genus. Thus, when there is substantial variation within the genus, one must describe a sufficient variety of species to reflect the variation within the genus.” In the present case, the genus is vast, as per the Claim Interpretation section, above. In contrast, the only species presented is a subset encompassing constructs comprising a cyclic peptide sequence consisting of the five variable amino acid sequence being selected from the groups consisting of SEQ ID NO: 1-4. As discussed in MPEP § 2163, the showing of an actual reduction to practice is not the only way to show possession. An adequate written description of the invention may be shown by any description of sufficient, relevant, identifying characteristics so long as a person skilled in the art would recognize that the inventor had possession of the claimed invention. That is, Applicants can also provide adequate written description support by describing sufficient distinguishing identifying characteristics to show that the claimed scope of the invention was "ready for patenting" as of the effectively filed date. In the present case, the disclosure does not detail any identifying characteristics of non-cyclic peptides or constructs with greater than five variable amino acid positions having an affinity to bind to the CHIKV E2 protein. Therefore, the disclosure reasonably lacks sufficient written description support for these embodiments. Consistent with the conclusion that Applicant only contemplated cyclic peptides, in the Description of the Related Art section on pp. 1-2, the specification discusses several patent documents, then discusses the difference from the present invention, stating “[w]hile all of these patents describe reagents developed against CHIKV E2, none are cyclic peptide-based” (e.g., as per para 0005). The specification then acknowledges that prior art U.S. PGPub 2015/0078999 A1 “relates to a cyclic peptide library. However, it does not show azide-functionalized cyclic peptide library compounds or the application of such a library to the whole protein among other differences” (e.g., as per para 0006). In conclusion, while the disclosure as originally filed shows ample written description support for cyclic peptides consisting of SEQ ID NOs: 1-4 in the variable positions and have affinity for CHIK V, with various compositions and numbers of polymer arm(s), including D and L stereoisomers, salts, and capture agents thereof, there lacks sufficient support for linear and non-cyclic peptide molecular constructs and constructs with SEQ ID NOs: 1-4 embedded in peptide sequences greater than the five amino acids. Since the claims encompass embodiments that are not supported by the original disclosure, they are properly rejected. Response to Arguments The 02/23/2026 remarks and declaration argue: the claims have sufficient written description support. Applicant's arguments have been fully considered but they are not persuasive for at least the following reasons. RE: “Nothing in these claims specifically requires the constructs to have linear peptide arrangements and amino acid sequences greater than 5. The Examiner focus on these possible embodiments is not warranted as that subject matter is not expressly recited in the claims. At best, it is unrecited subject matter.” (as per ¶14 of the declaration). This is not persuasive, at least because as per MPEP § 2111 -- Claim Interpretation; Broadest Reasonable Interpretation states (in part) that “[d]uring patent examination, the pending claims must be ‘given their broadest reasonable interpretation consistent with the specification.’" Further, in MPEP § 2163 -- Guidelines for the Examination of Patent Applications Under the 35 U.S.C. 112(a) or Pre-AIA 35 U.S.C. 112, first paragraph, "Written Description" Requirement, section (II)(A)(1) states (in part) that “[t]he entire claim must be considered, including the preamble language and the transitional phrase. ‘Preamble language’ is that language in a claim appearing before the transitional phase, e.g., before ‘comprising,’ ‘consisting essentially of,’ or ‘consisting of.’ The transitional term ‘comprising’ (and other comparable terms, e.g., ‘containing,’ and ‘including’) is ‘open-ended’ in that it covers the expressly recited subject matter, alone or in combination with unrecited subject matter.” RE: “What the Examiner seems to overlook is that similar results would be expected regardless of the peptide construct configurations” and the “binding ability has nothing to do with whether the peptide is a cyclic arrangement and/or has an amino acid sequence length of just five per se” (e.g., as per ¶20 of the declaration). In ¶18, the declaration states that “These constructs effectively function like an ‘epitope’ which the skilled artisan understands is the part of an antigen molecule to which an antibody binds, for example, and the specific amino acid sequence is key.” This is not persuasive at least because of Applicant’s own admission in the declaration that “the underlying research was performed and proved out with cyclic peptides and variable 5 amino acid sequences for CHIKV E2 protein using a Library of cyclic structures having a sequence length of just five amino acids” (e.g., as per ¶17 of the declaration) and that Applicant has presented no factual evidence to support their allegations that “binding ability has nothing to do with whether the peptide is a cyclic arrangement and/or has an amino acid sequence length of just five per se”. Without factual evidence, such allegations are not persuasive. As per MPEP § 2145, “arguments presented by applicant cannot take the place of factually supported objective evidence” citing In re Schulze, 346 F.2d 600, 602, 145 USPQ 716, 718 (CCPA 1965). In contrast, Applicant at ¶22 of the declaration acknowledges that according to the Das et al. paper, "superior performance of the macrocycles relative to the linear PCCs ... is anticipated," and that their “results showed varying differences based on the protein target: the macrocycles yield an average -log [KD (or EC50)] value of >7, while for linear PCCs, that value is <6”, and that “[i]n fact, some of the linear peptides mentioned showed stronger target binding compared to some of the cyclic constructs.” Thus, Applicant admits there can often be significant differences in binding between linear and cyclic constructs. This does not support allegations that “binding ability has nothing to do with whether the peptide is a cyclic arrangement and/or has an amino acid sequence length of just five per se”. RE: “"The compound library [for which the novel construct molecules were based on] may be a cyclic peptide library of cyclic peptides as illustrated in FIG. 2.’ Para. [0028] (emphasis added). Additionally, para. [0029] further couches a cyclic peptide in FIG. 2 as ‘the illustrated example"” (as per ¶19 of the declaration). RE: “In fact, the authors of the Das et al. paper-including myself-ultimately concluded: ‘However done, the general ability to target specific epitopes on specific proteins is enabling.’ p. 13223. (emphasis added)” (as per ¶21 of the declaration). RE: “[The Coppock et al., Peptide Science paper] … specifically mentions: ‘The PCC [protein catalyzed capture] process can be used to develop linear, branched, and/or cyclic peptide architectures.’ p. 2 (emphasis added)” (as per ¶23 of the declaration). RE: “In particular, linear and macrocyclic peptide screening strategies utilizing in situ 'click' chemistry have resulted in synthetic receptors with tunable affinities and selectivities” (citing Coppock et al., Sensing and BioSensing Research 22 (2019), 00248, pp. 1-8 as per ¶31 of the declaration). These and other similar statements allege that molecular constructs other than those having a cyclic peptide sequence consisting of one of SEQ ID NOs: 1-4 can or may exist or be found that might have affinity for the CHIKV E2 protein. However, while Applicant has shown some concrete data for some constructs (e.g., as per Fig. 4 and 8-9) comprising cyclic peptides that each consist of one of SEQ ID NO: 1-4, there is no factual evidence that any construct will bind, so long as it has somewhere in it one of SEQ ID NO:1-4. Further, while the declaration at several places relies on the Das et al. and Coppock et al. papers (e.g., ¶17, ¶18, ¶21, ¶22, ¶26, and ¶27), neither paper even mentions the CHIKV E2 protein nor do they provide any indication that binding to the CHIKV E2 protein can be predicted a priori. Further, regarding “incorporation by reference” practice, Applicant is respectfully invited to review 37 C.F.R. 1.57, which states (in part): (d) "Essential material" may be incorporated by reference, but only by way of an incorporation by reference to a U.S. patent or U.S. patent application publication, which patent or patent application publication does not itself incorporate such essential material by reference. "Essential material" is material that is necessary to: (1) Provide a written description of the claimed invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and set forth the best mode contemplated by the inventor of carrying out the invention as required by 35 U.S.C. 112(a); RE: “The CHIKV E2 antigen protein had been previously found to bind to linear epitopes. For example, U.S. Patent No. 9,738,704 B2 titled "Binding molecules against Chikungunya virus and uses thereof' issued to Lucile Watter et al. on Aug. 22, 2017” (as per ¶34 of the declaration). In response, the mere fact that some linear epitopes can bind to the CHIKV E2 protein does not reasonably support an allegation that any construct will bind, so long as it has somewhere in it one of SEQ ID NO:1-4. None of the constructs cited in the ‘704 patent comprise SEQ ID NO:1-4 and therefore its relevance is questionable. The same is concluded for International Patent Publication No. WO 2012/078116 A1 recited in ¶36 of the declaration. RE: “Taken together, these teachings incorporated by reference describe known linear arrangements used for peptide capture molecules. I believe that para. [0086]'s discussion of "tandem" peptide constructs" implies the same, i.e., a linear peptide. That passage clearly mentions adapting "known" peptide architectures and further explains that peptides could be expressed at the terminus of a protein, or a place between termini, which I believe clearly implies a linear structure (having endpoints) rather than being limited to a cyclic (or circular) structure” (at page 12 of the 02/23/2026 remarks quoting ¶24 of the declaration). In response, para [0086] is reprinted here for reference: Therapeutic agents and the peptide constructs disclosed herein can be linked or fused in known ways, optionally using the same type of linkers discussed elsewhere in this application. Preferred linkers will be substituted or unsubstituted alkyl chains, amino acid chains, polyethylene glycol chains, and other simple polymeric linkers known in the art. More preferably, if the therapeutic agent is itself a protein, for which the encoding DNA sequence is known, the therapeutic protein and antigen binding polypeptide can be coexpressed from the same synthetic gene, created using recombinant DNA techniques, as described above. The coding sequence for the antigen binding peptide construct can be fused in frame with that of the therapeutic protein, such that the peptide is expressed at the amino- or carboxy-terminus of the therapeutic protein, or at a place between the termini, if it is determined that such placement would not destroy the required biological function of either the therapeutic protein or the antigen binding peptide construct. A particular advantage of this general approach is that concatamerization of multiple, tandemly arranged peptide constructs is possible, thereby increasing the number and concentration of antigen binding sites associated with each therapeutic protein. In this manner, antigen binding avidity is increased, which would be expected to improve the efficacy of the recombinant therapeutic fusion protein. The final two sentences mention the “concateramerization of multiple, tandemly arranged peptide constructs” as a means to increase the “number and concentration of antigen binding sites” and that “[i]n this manner, antigen binding avidity is increased”. Respectfully, it is unclear how this means a linear peptide construct. And even if it does mean linear, it does not give factual evidence that any or all linear peptide/polypeptide constructs will have binding affinity for the CHIKV E2 protein so long as they have one of SEQ ID NO:1-4, as repeatedly asserted by Applicant. RE: “The Merck case is pertinent and should be followed” (e.g., as per the remarks at p. 13) and “The Examiner's position here is that the term ‘peptide’ in the claims cannot include linear ones, because Applicant only described cyclic peptides” (e.g., in the footnote of page 13 of the 02/23/2026 remarks) and “The Examiner suggests that the referenced paper must demonstrate that linear peptides (and longer amino acid sequences) to have an affinity to the CHIKV E2 protein” (e.g., as per the remarks at p. 13) and “[in Merck] the court required no showing that Integra Lifesciences’ peptide—having the Arg-Gly-Asp sequence—must demonstrate attachment to cyclic peptides” (e.g., as per pp. 13-14). In response, this is not an accurate interpretation of the Examiner’s position. As detailed in the Claim Interpretation and Response to Arguments, the position of the Examiner is that the scope of claims 1-20 does include both linear and cyclic peptides. However, as best as can be understood here, the remarks seem to be using the fact pattern of the Merck case to support an allegation that even though the specification only describes cyclic peptides, that one of ordinary skill in the art would or should interpret “cyclic peptides” as also including linear peptides, too. Further, the issue here is whether there is proper written description support in the specification to inform one of ordinary skill in the art that Applicant was in possession of the full scope of the claims, whereas the Merck case was concerned with patent infringement. As per MPEP § 2111, the interpretation of claim scope is different between patented claims and claims in an application being examined: “Patented claims are not given the broadest reasonable interpretation during court proceedings involving infringement and validity, and can be interpreted based on a fully developed prosecution record. In contrast, an examiner must construe claim terms in the broadest reasonable manner during prosecution as is reasonably allowed in an effort to establish a clear record of what applicant intends to claim. Thus, the Office does not interpret claims when examining patent applications in the same manner as the courts.” For at least the differences, Applicant’s arguments are not persuasive. RE: “On page 6 of the Advisory Action, the Examiner argues that he is not interpreting the claimed inventions as ‘requiring unrecited elements, but rather that the full scope of the claim may also include them.’ (emphasis in original). Applicant disagrees. Whether the claimed invention can include a peptide having a sequence of more than 5 amino acids is clearly referring to additional, unrecited elements of the claims beyond the group of sequences of five amino acids that are explicitly recited in the claims. Sequences of six-, seven-, eight- and even larger variable amino acids are clearly more than five” (e.g., as per p. 15 of the remarks). Respectfully, it is unclear what Applicant is disagreeing with here. In the Advisory Action, the Examiner was essentially agreeing with Applicant’s remarks of 12/18/2025, wherein Applicant stated that “the [comprising] language does not necessitate ‘additional, unrecited elements’ in the claim, only that they are not excluded by the claim” (e.g., p. 15 of the 12/18/2025 remarks). Conclusion No claims are allowed. Any inquiry concerning this communication or earlier communications from the examiner should be directed to JEREMY FLINDERS whose telephone number is (571)270-1022. The examiner can normally be reached M-F 10-6:00 EST. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Heather Calamita can be reached on (571)272-2876. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /JEREMY C FLINDERS/ Primary Examiner, Art Unit 1684
Read full office action

Prosecution Timeline

Show 1 earlier event
Aug 04, 2025
Non-Final Rejection mailed — §112
Sep 30, 2025
Response Filed
Oct 23, 2025
Final Rejection mailed — §112
Dec 18, 2025
Response after Non-Final Action
Feb 23, 2026
Response after Non-Final Action
Feb 23, 2026
Request for Continued Examination
Feb 27, 2026
Response after Non-Final Action
Jul 31, 2026
Non-Final Rejection mailed — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12747467
Spatially Encoded Biological Assays
3y 8m to grant Granted Sep 29, 2026
Patent 12716062
METHODS AND SYSTEMS FOR ISOLATING AND IDENTIFYING NUCLEIC ACID FROM A PLURALITY OF MICROORGANISMS AND VIRUSES
4y 9m to grant Granted Aug 25, 2026
Patent 12703884
A METHOD FOR DETECTING THE MUTATION AND METHYLATION OF TUMOR-SPECIFIC GENES IN CTDNA
4y 4m to grant Granted Aug 11, 2026
Patent 12699096
METHOD OF DETECTING LUNG CANCER
3y 3m to grant Granted Aug 04, 2026
Patent 12680138
SPATIAL TRANSCRIPTOMICS IN PIPS
4y 1m to grant Granted Jul 14, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
63%
Grant Probability
80%
With Interview (+17.1%)
3y 9m (~0m remaining)
Median Time to Grant
High
PTA Risk
Based on 615 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month